Immunological features predict treatment response for advanced solid tumors
Immune checkpoint therapy stimulates tumor infiltration by CD8 T cells to facilitate an antitumor response, but many advanced solid tumors do not respond to treatment. In the AMADEUS trial, researchers led by Padmanee Sharma, M.D., Ph.D., aimed to identify biomarkers that predict treatment response in patients with advanced solid tumors. The trial enrolled 39 patients who were divided into two groups based on pre-treatment levels of CD8 T cells. Those with low CD8 levels received a...